急诊观察病房路径治疗镰状细胞病无并发症血管闭塞事件的效果
该研究为前瞻性前后对照13年观察性研究,记录观察病房镰状细胞病路径的多年实施情况。路径以快速分诊识别无并发症血管闭塞事件患者、立即转入观察病房并启动患者自控镇痛,随后反复评估疼痛及识别其他并发症。路径于2006年4月启动,2009年6月(由路径内医师评估、仅经患者自控镇痛给药)和2010年10月(多学科管理及个体化给药)进行重大修订。结果:实施前入院率33%(123/368)、3日复诊率16%(60/368)、30日复诊率67%(248/368);近3年入院率降至20%(258/1276)、3日复诊率降至3.6%(46/1276)、30日复诊率降至41%(525/1276)。作者认为该路径有效提供快速治疗并减少入院,且实施成功还与外环境组织承诺、内环境学习氛围与领导参与、个体及流程等因素有关。
要点
- 实施前入院率为33%(123/368),路径优化后近3年降至20%(258/1276)。
- 实施前3日复诊率为16%(60/368),路径优化后近3年降至3.6%(46/1276)。
- 实施前30日复诊率为67%(248/368),路径优化后近3年降至41%(525/1276)。
- 路径以快速分诊识别无并发症血管闭塞事件、立即转入观察病房并启动患者自控镇痛为核心。
- 路径成功不仅依赖干预本身,还与外环境组织承诺、内环境学习氛围与领导参与、个体及流程有关。
适用人群与场景
- 急诊就诊的镰状细胞病无并发症血管闭塞事件患者。
- 研究场景为急诊科及基于急诊的观察病房。
处置流程与药物剂量
- 路径以快速分诊开始,识别无并发症血管闭塞事件患者后立即转入观察病房。
- 转入观察病房后启动患者自控镇痛,随后反复评估疼痛并识别其他并发症。
- 2009年6月修订后,医师评估在镰状细胞病路径内进行,且仅通过患者自控镇痛给药。
- 2010年10月修订后,实行多学科管理及个体化给药。
研究设计与关键结果
- 研究类型为前瞻性前后对照13年观察性研究,数据来自电子病历或观察病房数据库。
- 年度急诊就诊量范围为287至528人次。
- 实施前入院率为33%(123/368),3日复诊率为16%(60/368),30日复诊率为67%(248/368)。
- 路径优化后近3年入院率降至20%(258/1276),3日复诊率降至3.6%(46/1276),30日复诊率降至41%(525/1276)。
证据类型、等级与局限
- 证据类型为前瞻性前后对照观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用镰状细胞病路径治疗无并发症血管闭塞事件可有效提供快速治疗并减少入院。
- 作者认为,路径成功不仅源于干预及其优化,还与外环境组织承诺、内环境学习氛围与领导参与、个体及流程有关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: This was a prospective, pre-post, 13-year observational study documenting the multiyear implementation of an observation unit sickle cell pathway for patients with uncomplicated vaso-occlusive events.
METHODS: The sickle cell pathway begins with rapid triage to identify patients with uncomplicated vaso-occlusive events for immediate transfer to the observation unit and initiation of patient-controlled analgesia followed by repeated evaluations of pain and identification of other complications. Data were abstracted from the electronic medical record or observation unit database. The sickle cell pathway was initiated in April 2006. Major revisions of it were carried out in June 2009 (physician evaluation occurs in sickle cell pathway and only patient-controlled analgesia administration of medications) and October 2010 (multidisciplinary management and individual dosing).
RESULTS: Annual ED visits ranged between 287 and 528. The preimplementation hospital admission rate was 33% (123/368), 3-day return rate 16% (60/368), and 30-day return rate 67% (248/368). Refinements to the sickle cell pathway have resulted in a decrease in admission rate to 20% (258/1276); 3-day return rate, to 3.6% (46/1,276); and 30-day return rate, to 41% (525/1,276) for the past 3 years.
CONCLUSION: The use of a sickle cell pathway for the treatment of uncomplicated vaso-occlusive events has been effective in providing rapid treatment and reducing hospital admissions. However, it was not only the intervention and its refinement that made the sickle cell pathway successful. With the Consolidated Framework for Implementation Research, it was discerned that outer setting factors of organizational commitment to the care of patients with SCD, inner setting factors of learning climate and leadership engagement, individuals, and process contributed to the success of the sickle cell pathway.
参考来源
- Lyon M, Sturgis L, Lottenberg R, et al. Outcomes of an Emergency Department Observation Unit-Based Pathway for the Treatment of Uncomplicated Vaso-occlusive Events in Sickle Cell Disease. Ann Emerg Med. 2020. PMID: 32928457. doi:10.1016/j.annemergmed.2020.08.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。